Perrigo 将来の成長

NYSE:PRGO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4,801	128	513	659	5
12/31/2025	4,636	73	566	616	5
12/31/2024	4,436	-113	294	329	5
9/28/2024	4,392	-147	157	259	N/A
6/29/2024	4,428	-114	234	341	N/A
3/30/2024	4,556	1	301	385	N/A
12/31/2023	4,656	-4	324	406	N/A
9/30/2023	4,654	11	311	383	N/A
7/1/2023	4,630	-57	255	317	N/A
4/1/2023	4,559	-131	152	248	N/A
12/31/2022	4,452	-131	214	307	N/A
10/1/2022	4,401	-86	-102	16	N/A
7/2/2022	4,344	-88	162	301	N/A
4/2/2022	4,203	-135	112	235	N/A
12/31/2021	4,139	-131	-63	156	N/A
10/2/2021	4,087	-215	128	372	N/A
7/3/2021	4,047	-135	-157	91	N/A
4/3/2021	4,015	-11	214	465	N/A
12/31/2020	4,088	44	435	636	N/A
9/26/2020	4,358	77	371	615	N/A
6/27/2020	4,546	143	406	692	N/A
3/28/2020	4,746	140	136	465	N/A
12/31/2019	3,870	159	104	388	N/A
9/28/2019	4,710	247	272	493	N/A
6/29/2019	4,652	87	307	497	N/A
3/30/2019	4,689	114	374	515	N/A
12/31/2018	4,732	131	469	593	N/A
9/29/2018	4,820	123	505	616	N/A
6/30/2018	4,918	235	N/A	668	N/A
3/31/2018	4,969	129	N/A	677	N/A
12/31/2017	4,946	120	N/A	699	N/A
9/30/2017	4,994	-1,313	N/A	688	N/A
7/1/2017	5,025	-2,947	N/A	711	N/A
4/1/2017	5,127	-3,412	N/A	751	N/A
12/31/2016	5,281	-4,013	N/A	655	N/A
10/1/2016	5,308	-2,872	N/A	596	N/A
7/2/2016	5,320	-1,021	N/A	431	N/A
4/2/2016	5,395	-509	N/A	683	N/A
12/31/2015	5,015	-2	N/A	764	N/A
9/26/2015	4,997	144	N/A	1,139	N/A
6/27/2015	4,227	136	N/A	855	N/A
3/28/2015	4,217	203	N/A	1,028	N/A
12/27/2014	4,172	347	N/A	941	N/A
9/27/2014	4,079	190	N/A	790	N/A
6/28/2014	3,914	233	N/A	633	N/A
3/29/2014	3,884	192	N/A	575	N/A
12/28/2013	3,800	256	N/A	545	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PRGOは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: PRGO今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: PRGO今後 3 年以内に収益を上げることが予想されます。

収益対市場: PRGOの収益 ( 3.4% ) US市場 ( 8.9% ) よりも低い成長が予測されています。

高い収益成長: PRGOの収益 ( 3.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PRGOの自己資本利益率は、3年後には低くなると予測されています ( 4.9 %)。

Perrigo 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Perrigo Company plc Provides Revenue Guidance for the Fiscal Year 2024

Consensus EPS estimates fall by 288%

Perrigo Company plc Reaffirms Earnings Guidance for 2024

Consensus EPS estimates have been downgraded.

Price target decreased by 13% to US$38.75

Consensus EPS estimates fall by 24%

Recent updates

New major risk - Dividend sustainability

Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 profit in 3Q 2023)

Perrigo Company plc Provides Revenue Guidance for the Fiscal Year 2024

Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276

Second quarter dividend of US$0.28 announced

Perrigo Company plc Announces Quarterly Dividend, Payable on December 17, 2024

Perrigo Company plc to Report Q3, 2024 Results on Nov 06, 2024

Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary

Upcoming dividend of US$0.28 per share

Advisor recently sold US$969k worth of stock

Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276

Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer

The Play On Perrigo

Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276

Second quarter dividend of US$0.28 announced

Second quarter 2024 earnings released: US$0.77 loss per share (vs US$0.066 profit in 2Q 2023)

Perrigo Company plc Reports Impairment Charges for the Second Quarter Ended June 29, 2024

Perrigo Company plc to Report Q2, 2024 Results on Aug 02, 2024

President exercised options to buy US$477k worth of stock.

Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc.

Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024

Perrigo Company plc Announces Executive Changes

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

Upcoming dividend of US$0.28 per share

Consensus EPS estimates fall by 288%

Perrigo Company plc Reaffirms Earnings Guidance for 2024

New major risk - Financial position

First quarter 2024 earnings released: EPS: US$0.03 (vs US$0.008 loss in 1Q 2023)

Fourth quarter dividend of US$0.28 announced

Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024

Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million.

Perrigo Company plc to Report Q1, 2024 Results on May 07, 2024

Benign Growth For Perrigo Company plc (NYSE:PRGO) Underpins Its Share Price

Perrigo Company plc, Annual General Meeting, May 02, 2024

Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors

Consensus EPS estimates have been downgraded.

Full year 2023 earnings: EPS misses analyst expectations

Perrigo Company plc Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Price target decreased by 13% to US$38.75

Consensus EPS estimates fall by 24%

Perrigo Company plc Increases its Quarterly Dividend, Payable on March 26, 2024

Perrigo Company plc to Report Q4, 2023 Results on Feb 27, 2024

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

The Market Doesn't Like What It Sees From Perrigo Company plc's (NYSE:PRGO) Revenues Yet

Upcoming dividend of US$0.27 per share at 3.6% yield

President recently bought US$319k worth of stock

Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying

Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q3, 2023 Results on Nov 07, 2023

Perrigo Company plc Announces Executive Changes

The Prognosis For Perrigo

Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q2, 2023 Results on Aug 08, 2023

Perrigo Company plc Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive

Perrigo Outlook Healed By Repositioning

Perrigo Company plc Appoints Patrick Lockwood-Taylor as Its New Chief Executive Officer

Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge

Perrigo Company plc Announces FDA Approval of Opill®? for Over-The-Counter Use

Perrigo Company plc Reaffirms Sales Guidance for the Fiscal Year 2023

Perrigo Announces Quarterly Dividend, Payable on June 20, 2023

Perrigo raises dividend by 5% to $0.273/share

Perrigo Company plc to Report Q4, 2022 Results on Feb 27, 2023

Theodore R. Samuels Not to Stand for Re-Election to the Perrigo Company plc's Board of Directors

Perrigo: Still Languishing But Short-Term Trend Offers Encouragement

Perrigo Company plc Provides Earnings Guidance for the Fiscal Year 2022

Perrigo Non-GAAP EPS of $0.56 misses by $0.11, revenue of $1.1B misses by $40M, lowers FY adj. EPS guidance

Perrigo Company plc Announces Quarterly Dividend, Payable on December 20, 2022